| Literature DB >> 27871303 |
Andria Rusk1,2, Linda Highfield3, J Michael Wilkerson3, Melissa Harrell3, Andrew Obala4,5, Benjamin Amick6,7.
Abstract
BACKGROUND: Most patients with malaria seek treatment first in retail drug shops. Myriad studies have examined retailer behaviours and characteristics to understand the determinants to these behaviours. Geospatial methods are helpful in discovering if geographic location plays a role in the relationship between determinants and outcomes. This study aimed to discover if spatial autocorrelation exists in the relationship between determinants and retailer behaviours, and to provide specific geographic locations and target behaviours for tailoring future interventions.Entities:
Keywords: Antimalarial drugs; Behavior; Geographically weighted regression; Malaria; Private sector
Mesh:
Substances:
Year: 2016 PMID: 27871303 PMCID: PMC5117492 DOI: 10.1186/s12936-016-1599-5
Source DB: PubMed Journal: Malar J ISSN: 1475-2875 Impact factor: 2.979
Fig. 1Map of Kenya, with the Bungoma district containing the study area inset
Fig. 2Map of the WHDSS study area showing shop locations, adapted from Rusk et al. [18]
Association between medicine retailer demographics and study outcomes
| % (n) | Unadjusted odds ratios and (95% confidence intervals; p values) | |||
|---|---|---|---|---|
| Recommended ACTs as malaria treatment for adult patients | Recommended ACTs as malaria treatment for under 5 patients | Reported selling ACTs more than any other antimalarial | ||
| Age | ||||
| Under 30 | 38% (33) | 1 (reference) | 1 (reference) | 1 (reference) |
| Between 30 and 40 | 44% (38) | 0.65 (0.25–1.67; 0.371) | 1.08 (0.42–2.75; 0.872) | 0.99 (0.38–2.54; 0.978) |
| Over 40 | 17% (15) | 0.98 (0.28–3.39; 0.968) | 0.80 (0.23–2.76; 0.724) | 0.90 (0.26–3.13; 0.875) |
| Gender | ||||
| Female | 77% (67) | 1 (reference) | 1 (reference) | 1 (reference) |
| Male | 23% (20) | 1.7 (0.60–4.79; 0.317) | 0.59 (0.21–1.66; 0.317) | 0.93 (0.34–2.57; 0.887) |
| Education level | ||||
| Secondary or below | 32% (28) | 1 (reference) | 1 (reference) | 1 (reference) |
| Above secondary | 68% (59) | 1.1 (0.45–2.71; 0.836) | 1.4 (0.56–3.48; 0.475) | 1.42 (0.56–3.59; 0.461) |
| Health qualification type | ||||
| Untrained | 14% (12) | 1 (reference) | 1 (reference) | 1 (reference) |
| Pharmacy | 40% (35) | 5.75 (1.31–25.29; 0.021)** | 1.5 (0.38–5.93; 0.563) | 5.29 (1.01–27.75; 0.049)** |
| Nurse/midwife | 46% (40) | 3.67 (0.86–15.59; 0.079)* | 2 (0.52–7.72; 0.315) | 3.33 (0.64–17.26; 0.151)* |
| Health qualification level | ||||
| Untrained | 14% (12) | 1 (reference) | 1 (reference) | 1 (reference) |
| Assistant level | 25% (22) | 3.0 (0.67–14.15; 0.165)* | 2.4 (0.55–10.38; 0.241)* | 5 (0.88–28.29; 0.07)* |
| Professional level | 61% (53) | 5.37 (1.29–22.26; 0.021)** | 1.53 (0.41–5.73; 0.525) | 3.83 (0.76–19.22; 0.102)* |
| Attended malaria workshop | ||||
| No | 59% (51) | 1 (reference) | 1 (reference) | 1 (reference) |
| Yes | 41% (35) | 1.63 (0.68–3.92; 0.277) | 1.64 (0.69–3.91; 0.264) | 2.38 (0.98–5.75; 0.055)* |
* Significant at p < 0.2
** Significant at p < 0.05
Association between medicine retailer knowledge, behaviours and study outcomes
| % (n) | Unadjusted odds ratios and (95% confidence intervals; p-values) | |||
|---|---|---|---|---|
| Recommended ACTs as malaria treatment for adult patients | Recommended ACTs as malaria treatment for under 5 patients | Reported selling ACTs more than any other antimalarial | ||
| Identified ACT as MOH-recommended antimalarial | ||||
| No | 37% (32) | 1 (reference) | 1 (reference) | 1 (reference) |
| Yes | 63% (55) | 3.0 (1.21–7.47; 0.018)** | 2.34 (0.93–5.88; 0.070)* | 2.36 (0.92–6.03; 0.073)* |
| Recommended ACT to adults | ||||
| No | 45% (39) | – | 1 (reference) | 1 (reference) |
| Yes | 55% (48) | – | 5.37 (2.08–13.87; 0.001)** | 8.89 (3.11–25.39; < 0.001)** |
| Recommended ACT to children | ||||
| No | 55% (48) | 1 (reference) | – | 1 (reference) |
| Yes | 45% (39) | 5.37 (2.08–13.87; 0.001)** | – | 3.76 (1.52–9.28; 0.004)** |
| Sold ACTs more than any other antimalarial | ||||
| No | 59% (51) | 1 (reference) | 1 (reference) | – |
| Yes | 41% (36) | 8.89 (3.11–25.39; < 0.001)** | 3.76 (1.52–9.28; 0.004)** | – |
| Gave Fansidar to a mother requesting it | ||||
| No | 81% (70) | 1 (reference) | 1 (reference) | 1 (reference) |
| Yes | 18% (16) | 0.67 (0.21–2.01; 0.461) | 0.36 (0.11–1.25; 0.109)* | 0.94 (0.30–2.94; 0.919) |
* Significant at p < 0.2
** Significant at p < 0.05
Association of retail drug shop characteristics and study outcomes
| % (n) | Unadjusted odds ratios and (95% confidence intervals; p values) | |||
|---|---|---|---|---|
| Recommended ACTs as malaria treatment for adult patients | Recommended ACTs as malaria treatment for under 5 patients | Reported selling ACTs more than any other antimalarial | ||
| Offers diagnostic testing | ||||
| No | 90% (78) | 1 (reference) | 1 (reference) | 1 (reference) |
| Yes | 10% (9) | 3.16 (0.62–16.17; 0.167)* | 0.58 (0.14–2.5; 0.468) | 1.15 (0.29–4.62; 0.844) |
| Total number of staff | ||||
| Only 1 staff member | 60% (52) | 1 (reference) | 1 (reference) | 1 (reference) |
| 2 staff members | 32% (28) | 1.94 (0.76–5; 0.168)* | 1.48 (0.59–3.72; 0.409) | 1.74 (0.68–4.41; 0.245)* |
| 3–6 staff members | 7% (6) | 5.4 (0.59–49.47; 0.136)* | 2.95 (0.5–17.6; 0.235)* | 1.74 (0.32–9.48; 0.524) |
| Open weekends | ||||
| Close weekends | 17% (15) | 1 (reference) | 1 (reference) | 1 (reference) |
| Open weekends | 83% (72) | 2.1 (0.68–6.53; 0.2)* | 1.27 (0.41–3.94; 0.68) | 2.2 (0.64–7.57; 0.211)* |
| Open hours per day | ||||
| Fewer than 10 h | 60% (52) | 1 (reference) | 1 (reference) | 1 (reference) |
| 10 or more hours | 39% (34) | 1.83 (0.75–4.46; 0.181)* | 0.51 (0.21–1.23; 0.132)* | 1.74 (0.72–4.18; 0.218)* |
* Significant at p < 0.2
** Significant at p < 0.05
Parameter estimates from the geographically geographically-weighted global regression model for the outcome of recommending the correct malaria treatment to adults
| Estimate | Standard error | |
|---|---|---|
| Intercept | −2.331 | 0.88* |
| Identified ACT as MOH-recommended antimalarial | 0.645 | 0.559 |
| Recommended correct treatment to children under 5 | 1.307 | 0.544* |
| Had health-related training | 1.052 | 0.865 |
| Sold ACTs more than any other antimalarial | 1.787 | 0.566* |
* Denotes statistical significance
Parameter estimates from the geographically geographically-weighted global regression model for the outcome of recommending the correct malaria treatment to children under five
| Estimate | Standard error | |
|---|---|---|
| Intercept | −1.354 | 0.522* |
| Identified ACT as MOH-recommended antimalarial | 0.602 | 0.54 |
| Recommended correct treatment to adults | 1.411 | 0.562* |
| Gave Fansidar to a mother requesting it | −0.982 | 0.685 |
| Sold ACTs more than any other antimalarial | 0.825 | 0.545 |
| Female | −0.89 | 0.621 |
* Statistical significance
Parameter estimates from the geographically geographically-weighted global regression model for the outcome of selling ACT medicines more than any other anti-malarial
| Estimate | Standard error | |
|---|---|---|
| Intercept | −2.407 | 0.615* |
| Identified ACT as MOH-recommended antimalarial | 0.448 | 0.561 |
| Recommended correct treatment to children under 5 | 0.742 | 0.533 |
| Recommended correct treatment to adults | 1.8 | 0.58* |
| Attended malaria workshop | 0.781 | 0.521 |
* Statistical significance
Comparison of global and local Logistic model diagnostics for each outcome
| Global model | Local model | |
|---|---|---|
| Recommended correct treatment to adults | ||
| Akaike information criterion | 97.85 | 91.47 |
| Corrected akaike information criterion | 98.58 | 92.47 |
| Deviance | 87.85 | 79.78 |
| Recommended correct treatment to children under 5 | ||
| Akaike information criterion | 106.95 | 99.07 |
| Corrected akaike information criterion | 108.01 | 101.33 |
| Deviance | 94.95 | 81.49 |
| Sold ACTs more than any other antimalarial | ||
| Akaike information criterion | 101.28 | 100.75 |
| Corrected akaike information criterion | 102.03 | 102.04 |
| Deviance | 91.28 | 87.48 |
Fig. 3Local coefficient estimates for the statistically significant determinants to the outcome recommending correct antimalarial treatment to adults, across the Webuye Demographic Health Surveillance Site study area. Panel 1 shows the local coefficient estimates for the statistically significant determinant recommending the correct antimalarial treatment to children under 5 Panel 2 shows the local coefficient estimates for the statistically significant determinant having health-related training Panel 3 shows the local coefficient estimates for the statistically significant determinant correctly identifying ACTs as the MOH-recommended first-line treatment for uncomplicated malaria The darker the circle indicates the stronger the association
Fig. 4Local coefficient estimates for the statistically significant determinants to the outcome recommending correct antimalarial treatment to children under 5, across the Webuye Demographic Health Surveillance Site study area. Panel 1 shows the local coefficient estimates for the statistically significant determinant recommending correct treatment to adults Panel 2 shows the local coefficient estimates for the statistically significant determinant giving Fansidar® to a mother requesting it The darker the circle indicates the stronger the association
Fig. 5Local coefficient estimates for the statistically significant determinant to the outcome selling ACTs more than any other antimalarial medication, across the Webuye Demographic Health Surveillance Site study area. Panel 1 shows the local coefficient estimates for the only statistically significant determinant: having attended a malaria workshop The darker the circle indicates the stronger the association
Fig. 6Spatial distribution of pseudo-R2 values for the full model of each outcome, across the Webuye Demographic Health Surveillance Site study area. Panel 1 shows the spatial distribution of pseudo-R2 values for the full model of the outcome recommending correct treatment to adults Panel 2 shows the spatial distribution of pseudo-R2 values for the full model of the outcome recommending correct treatment to children under 5 Panel 3 shows the spatial distribution of pseudo-R2 values for the full model of the outcome selling ACTs more than another antimalarial The darker the circle indicates the better the model fit